These results highlight the need for a customised paradigm in evaluating the reproductive effects of GLP-1 receptor agonists, suggesting that metabolic state and inherent ovarian disease should be assessed independently when analysing reproductive outcomes. This evidence concerns the gene GLP1R and ovarian disorder.